Are durvalumab and durvalumab the same drug? What are the differences and similarities between the two?
Durvalumab and durvalumab are actually the same drug, but their names are translated differently. Durvalumab is the transliteration name of Durvalumab, while durvalumab is another transliteration of the full name of the drug according to Chinese naming rules. Regardless of the translation, it refers to the same anti-PD-L1 monoclonal antibody, which is used to treat certain types of cancer, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
In terms of its mechanism of action, durvalumab (durvalumab) blocks the binding of PD-L1 protein to PD-1 receptors, thereby lifting the immune suppression of T cells, allowing the body's immune system to more effectively identify and attack cancer cells. This mechanism is similar to other PD-1/PD-L1 inhibitors and is widely used in immunotherapy. The two are completely identical in terms of indications, mechanisms of action, side effects, etc., and there is no need to distinguish between different names when using them.

Although the names are different, there is no difference between durvalumab and durvalumab in terms of clinical application, dosage and drug specifications. At present, the drug has been marketed in many countries at home and abroad, with the main specifications being 120mg/2.4mL and 500mg/10mL injections. When purchasing drugs, patients only need to confirm the English name of the drug "Durvalumab". Regardless of the Chinese translation on the outer packaging of the drug, they can ensure that they are purchasing the same drug.
In general, durvalumab and durvalumab only have different translated names and are essentially the same anti-PD-L1 monoclonal antibody drugs. Patients do not need to have doubts due to different names when choosing, but should pay attention to its indications, treatment options and doctors' professional advice to ensure that the drug is used rationally to obtain the best therapeutic effect.
Reference materials:https://www.imfinzi.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)